RxDoctor Payments Data

Molly Price, MD

Neurology · Annapolis, MDNPI 1831226299

Payments from drug & device makers

$31,745in general payments, 2019–2025

Across 1,808 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Biogen$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Pfizer$2K
  • Novartis$2K
  • Amgen$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$4501%
  • Speaking & faculty fees$1070%
  • Food & beverage$31,12598%
  • Education$630%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)378$4,559
Biogen176$3,444
Teva Pharmaceuticals USA, Inc.77$1,868
Pfizer91$1,701
Novartis111$1,579
Amgen(2 entities)79$1,471
UCB, Inc.61$1,434
Lilly USA, LLC85$1,412
Lundbeck LLC54$1,074
Genentech USA, Inc.39$887
Eisai Inc.38$696
Sunovion Pharmaceuticals Inc.40$694
CSL Behring33$679
Neurelis, Inc.34$637
Amneal Pharmaceuticals LLC32$632
Neurocrine Biosciences, Inc.27$546
Biohaven Pharmaceutical Holding Company Ltd.41$530
Bristol Myers Squibb28$459
Sanofi19$343
Argenx US, Inc.12$333
Biohaven Pharmaceuticals, Inc.29$314
Supernus Pharmaceuticals, Inc.38$306
Greenwich Biosciences, Inc.13$252
Alnylam Pharmaceuticals Inc.10$252
Kyowa Kirin, Inc.11$247
EMD Serono, Inc.13$244
Takeda Pharmaceuticals U.S.A., Inc.8$241
AstraZeneca(2 entities)10$237
Avanir Pharmaceuticals, Inc.14$224
Grifols USA, LLC10$219
Acadia Pharmaceuticals Inc11$214
Sumitomo Pharma America, Inc.11$208
Banner Life Sciences, LLC10$205
Acorda Therapeutics, Inc10$200
MDD US Operations, LLC7$197
SK Life Science, Inc.7$190
Impel Pharmaceuticals Inc.9$189
Upsher-smith Laboratories LLC8$172
TG Therapeutics, Inc.7$170
Catalyst Pharmaceuticals, Inc.7$161
Adamas Pharmaceuticals, Inc.9$155
Octapharma USA, Inc.7$150
E.r. Squibb & Sons, L.L.C.7$134
Merz Pharmaceuticals, LLC4$120
Vanda Pharmaceuticals Inc.5$119
Tanabe Pharma America, Inc.5$113
Johnson & Johnson6$101
Scilex Pharmaceuticals Inc.5$98
Axsome Therapeutics, Inc.4$93
Promius Pharma LLC5$82
Sanofi-aventis U.S. LLC4$79
Akcea Therapeutics, Inc.1$72
Xeris Pharmaceuticals, Inc.3$63
Aquestive Therapeutics, Inc.3$62
Livanova USA, Inc.2$62
Impel Pharmaceuticals LLC2$61
Mallinckrodt Enterprises LLC2$61
Currax Pharmaceuticals LLC4$60
Ipsen Biopharmaceuticals, Inc3$58
Nevro Corp.2$58

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,745 in reported general payments places this provider in the 80th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$724,498
Medicare patients
427
Services billed
16,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm65$101,574
Rufinamide11$89,847
Nurtec OdtRimegepant Sulfate80$89,245
UbrelvyUbrogepant69$80,985
FycompaPerampanel33$54,123
KeppraLevetiracetam15$38,802
Tiagabine Hcl14$20,282
Lacosamide76$15,982
Levetiracetam228$13,310
DilantinPhenytoin Sodium Extended25$8,905
Ajovy SyringeFremanezumab-Vfrm11$8,568
Clobazam19$6,302
Divalproex Sodium ErDivalproex Sodium19$6,029
Carbamazepine ErCarbamazepine43$5,917
Tegretol XrCarbamazepine12$4,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin, Dilantin$1,701$100,925122 claims
AbbVieUbrelvy$4,559$80,98569 claims
Eisai Inc.Fycompa$696$54,12333 claims
Upsher-smith Laboratories LLCTopiramate$172$90049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 neurology providers in Maryland.

Other neurology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →